The Latest in IT Security

An experimental drug designed to treat patients infected with the deadly ebola virus could be back on track for human testing following a decision from the US Food and Drug Administration today. The agency lifted a halt on testing TKM-Ebola, a drug made by Canadian pharmaceutical company Tekmira, that up until last month had been given special fast-track status by the FDA to help speed it through various regulatory hurdles. The FDA put the brakes on that process in early July, asking for more information on how the drug works when given to patients in higher doses. Today Tekmira said that it had received a verbal confirmation from the FDA that it could test the drug on patients who were actually infected with the virus, while connecting the move to the ebola outbreak in West Africa thats tallied up 932 deaths thus far.